<DOC>
	<DOC>NCT00018382</DOC>
	<brief_summary>This study examines the use of insulin-sensitizing compounds, as therapeutic agents for cognitive impairment in Alzheimer's disease.</brief_summary>
	<brief_title>Insulin, Neurogenetics and Memory in Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>Men and women with mild Alzheimer's Disease without serious medical or psychiatric comorbid conditions.</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2004</verification_date>
</DOC>